波生坦与充血性心力衰竭中的内皮素系统
Bosentan and the endothelin system in congestive heart failure.
作者信息
Ellahham S H, Charlon V, Abassi Z, Calis K A, Choucair W K
机构信息
Division of Cardiology, Washington Hospital Center, DC 20010, USA.
出版信息
Clin Cardiol. 2000 Nov;23(11):803-7. doi: 10.1002/clc.4960231128.
Abstract
The endothelin system appears to play an important role in the pathophysiology of congestive heart failure (CHF). Endothelin receptor antagonists represent a novel class of agents that are being evaluated for their potential benefits in treating various cardiovascular disorders. Bosentan is an orally active endothelin receptor antagonist that has been studied for the treatment of CHF. Early clinical experience with bosentan has confirmed some benefits on hemodynamic parameters in patients with CHF. Its role in slowing the progression of the disease and improving survival remains to be elucidated.
摘要
内皮素系统似乎在充血性心力衰竭（CHF）的病理生理学中发挥重要作用。内皮素受体拮抗剂是一类新型药物，目前正在评估其在治疗各种心血管疾病方面的潜在益处。波生坦是一种口服活性内皮素受体拮抗剂，已被用于研究治疗CHF。波生坦的早期临床经验已证实对CHF患者的血流动力学参数有一些益处。其在减缓疾病进展和提高生存率方面的作用仍有待阐明。
相似文献
1
Bosentan and the endothelin system in congestive heart failure.波生坦与充血性心力衰竭中的内皮素系统
Clin Cardiol. 2000 Nov;23(11):803-7. doi: 10.1002/clc.4960231128.
2
Endothelin and endothelin receptor antagonism in heart failure.心力衰竭中的内皮素与内皮素受体拮抗作用
J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S69-73. doi: 10.1097/00005344-200000002-00016.
3
Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?内皮素受体拮抗剂用于治疗充血性心力衰竭：未来的一种新治疗原则？
J Am Coll Cardiol. 2001 May;37(6):1493-505. doi: 10.1016/s0735-1097(01)01210-4.
4
Hemodynamic effects of bosentan in patients with chronic heart failure.波生坦对慢性心力衰竭患者的血流动力学影响。
Heart Fail Rev. 2001 Dec;6(4):325-34. doi: 10.1023/a:1011460426786.
5
Endothelin antagonists and heart failure.内皮素拮抗剂与心力衰竭
Curr Hypertens Rep. 2002 Feb;4(1):85-92. doi: 10.1007/s11906-002-0058-6.
6
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.非肽类内皮素-1受体拮抗剂波生坦对人体的急性和短期影响。
Cardiovasc Drugs Ther. 1997 Jan;10(6):717-25. doi: 10.1007/BF00053029.
7
Endothelin and heart failure.内皮素与心力衰竭
Heart Fail Rev. 2001 Dec;6(4):335-40. doi: 10.1023/a:1011464510857.
8
Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.内源性内皮素在慢性心力衰竭中的作用：内皮素拮抗剂长期治疗对生存率、血流动力学和心脏重塑的影响。
Circulation. 1997 Sep 16;96(6):1976-82. doi: 10.1161/01.cir.96.6.1976.
9
Endothelin antagonism with bosentan: current status and future perspectives.波生坦的内皮素拮抗作用：现状与未来展望。
Cardiovasc Drug Rev. 2002 Winter;20(1):1-18. doi: 10.1111/j.1527-3466.2002.tb00078.x.
10
Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).内皮素在慢性心力衰竭清醒大鼠血压维持中的作用。内皮素受体拮抗剂Ro 47 - 0203（波生坦）的急性效应。
Circulation. 1994 Nov;90(5):2510-8. doi: 10.1161/01.cir.90.5.2510.
引用本文的文献
1
Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure.米贝地尔在阿霉素诱导心力衰竭大鼠模型中心脏保护作用的研究。
Iran J Med Sci. 2021 Mar;46(2):136-143. doi: 10.30476/ijms.2019.82057.0.
2
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.波生坦的单剂量和多剂量药代动力学及其与酮康唑的相互作用。
Br J Clin Pharmacol. 2002 Jun;53(6):589-95. doi: 10.1046/j.1365-2125.2002.01608.x.
本文引用的文献
1
The pharmacology of bosentan.波生坦的药理学
Expert Opin Investig Drugs. 1998 Jul;7(7):1173-92. doi: 10.1517/13543784.7.7.1173.
2
The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.内皮素受体拮抗剂波生坦对原发性高血压患者血压的影响。波生坦高血压研究组。
N Engl J Med. 1998 Mar 19;338(12):784-90. doi: 10.1056/NEJM199803193381202.
3
Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling.内源性内皮素在慢性心力衰竭中的作用：内皮素拮抗剂长期治疗对生存率、血流动力学和心脏重塑的影响。
Circulation. 1997 Sep 16;96(6):1976-82. doi: 10.1161/01.cir.96.6.1976.
4
Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.非肽类内皮素-1受体拮抗剂波生坦对人体的急性和短期影响。
Cardiovasc Drugs Ther. 1997 Jan;10(6):717-25. doi: 10.1007/BF00053029.
5
Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans.内皮素受体亚型在人体对内皮素-1的全身及肾脏反应中的作用。
J Am Soc Nephrol. 1997 Jan;8(1):32-9. doi: 10.1681/ASN.V8132.
6
Endothelins in the normal and diseased kidney.正常及患病肾脏中的内皮素
Am J Kidney Dis. 1997 Jan;29(1):2-26. doi: 10.1016/s0272-6386(97)90004-4.
7
Differential regulation of renal regional blood flow by endothelin-1.内皮素-1对肾局部血流的差异性调节
Am J Physiol. 1996 Dec;271(6 Pt 2):F1166-72. doi: 10.1152/ajprenal.1996.271.6.F1166.
8
Evidence that both ETA and ETB receptor subtypes are involved in the in vivo aldosterone secretagogue effect of endothelin-1 in rats.有证据表明，ETA和ETB受体亚型均参与了内皮素-1对大鼠体内醛固酮促分泌素的作用。
Res Exp Med (Berl). 1996;196(3):145-52. doi: 10.1007/BF02576836.
9
Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.内皮素受体拮抗剂波生坦在健康人体受试者中的药代动力学和药效学
Clin Pharmacol Ther. 1996 Aug;60(2):124-37. doi: 10.1016/S0009-9236(96)90127-7.
10
Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure.内皮素受体阻断对慢性心力衰竭犬的短期血流动力学影响
Circulation. 1996 Aug 15;94(4):779-84. doi: 10.1161/01.cir.94.4.779.
Zotero 插件